Recently Approved Lung Cancer Treatments

Find out below about the lung cancer treatments approved by the FDA since January 2018.


March 2019

  • FDA approved atezolizamab (Tecentriq) in combination with chemotherapy for first line treatment of extensive stage SCLC. Read More

December 2018

  • FDA approved atezolizumab (Tecentriq) in combination with chemotherapy as a first line treatment of non-squamous non-small cell lung cancer (NSCLC) that has metastasized. Read More

November 2018

  • FDA approved lorlatinib (Lorbrena) as a second or third line treatment for patients with ALK+ metastatic non-small cell lung cancer (NSCLC). Read More

October 2018

  • FDA approved pembrolizumab (Keytruda) in combination with chemotherapy as a first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC). Read More

September 2018

  • FDA approved dacomitinib (Vizimpro) as a first-line treatment for patients with EFGR+ metastatic non-small cell lung cancer (NSCLC). Read More

August 2018

  • FDA approved pembrolizumab (Keytruda) in combination with chemotherapy as a first-line treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC). Read More
  • FDA approved nivolumab (Opdivo) as a third-line treatment for patients with metastatic small cell lung cancer (SCLC). Read More

April 2018

  • FDA approved osimertinib (Tagrisso) as a first-line treatment for EGFR+ patients with metastatic non-small cell lung cancer (NSCLC). Read More

February 2018

  • FDA approved durvalumab (Imfinzi) after chemoradiation treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC). Read More

January 2018

  • FDA approved afatinib (Gilotrif) for a broadened indication in first-line treatment of EGFR+ patients with metastatic non-small cell lung cancer (NSCLC). Read More